NO995382L - Lentivirus baserte genoverfoeringsvektorer - Google Patents

Lentivirus baserte genoverfoeringsvektorer

Info

Publication number
NO995382L
NO995382L NO995382A NO995382A NO995382L NO 995382 L NO995382 L NO 995382L NO 995382 A NO995382 A NO 995382A NO 995382 A NO995382 A NO 995382A NO 995382 L NO995382 L NO 995382L
Authority
NO
Norway
Prior art keywords
vector
eiav
expression system
genome
defective
Prior art date
Application number
NO995382A
Other languages
English (en)
Norwegian (no)
Other versions
NO995382D0 (no
Inventor
John C Olsen
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of NO995382D0 publication Critical patent/NO995382D0/no
Publication of NO995382L publication Critical patent/NO995382L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO995382A 1997-05-13 1999-11-03 Lentivirus baserte genoverfoeringsvektorer NO995382L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4689197P 1997-05-13 1997-05-13
PCT/US1998/010144 WO1998051810A1 (en) 1997-05-13 1998-05-12 Lentivirus-based gene transfer vectors

Publications (2)

Publication Number Publication Date
NO995382D0 NO995382D0 (no) 1999-11-03
NO995382L true NO995382L (no) 2000-01-13

Family

ID=21945954

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995382A NO995382L (no) 1997-05-13 1999-11-03 Lentivirus baserte genoverfoeringsvektorer

Country Status (13)

Country Link
US (3) US6277633B1 (de)
EP (1) EP0981636B1 (de)
JP (1) JP4390860B2 (de)
KR (1) KR100556864B1 (de)
CN (1) CN1247788C (de)
AT (1) ATE291632T1 (de)
AU (1) AU741747B2 (de)
CA (1) CA2288328A1 (de)
DE (1) DE69829471T2 (de)
IL (1) IL132463A0 (de)
NO (1) NO995382L (de)
NZ (1) NZ500740A (de)
WO (1) WO1998051810A1 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
US20040076613A1 (en) * 2000-11-03 2004-04-22 Nicholas Mazarakis Vector system
US6818209B1 (en) * 1998-05-22 2004-11-16 Oxford Biomedica (Uk) Limited Retroviral delivery system
US7635687B2 (en) * 1997-06-04 2009-12-22 Oxford Biomedica (Uk) Limited Vector system
CA2304983A1 (en) * 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
GB2356200B (en) * 1997-12-22 2002-05-01 Oxford Biomedica Ltd Retroviral vectors
ES2373406T3 (es) * 1997-12-22 2012-02-03 Oxford Biomedica (Uk) Limited Vectores basados en el virus de la anemia infecciosa equina (vaie).
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
WO2000040741A2 (en) * 1999-01-07 2000-07-13 The Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services, The National Institutes Of Health Lentivirus vector system
US6790657B1 (en) 1999-01-07 2004-09-14 The United States Of America As Represented By The Department Of Health And Human Services Lentivirus vector system
WO2000055378A1 (en) * 1999-03-16 2000-09-21 Dana-Farber Cancer Institute, Inc. Lentiviral vector system for high quantity screening
CN1173036C (zh) * 1999-04-21 2004-10-27 卫生部艾滋病预防与控制中心 马传染性贫血病毒驴白细胞弱毒疫苗株的全长基因序列
CA2388337C (en) 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
CN1321182C (zh) * 1999-12-30 2007-06-13 卫生部艾滋病预防与控制中心 马传染性贫血病毒代表毒株的全基因克隆及其应用
GB0009760D0 (en) * 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
AU8710301A (en) * 2000-09-09 2002-03-22 Akzo Nobel Nv Eiav chimeric vaccine and diagnostic
GB0024550D0 (de) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2002079482A2 (en) * 2000-11-16 2002-10-10 Rigel Pharmaceuticals, Inc. In vitro transcribed retroviral genomes, methods for their production and methods of use
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
IL157335A0 (en) * 2001-03-13 2004-02-19 Novartis Ag Lentiviral packaging constructs
US7211247B2 (en) 2001-04-09 2007-05-01 University Of Southern California Lentivirus vectors for gene transfer to alveolar epithelial cells
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
ATE527347T1 (de) 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
RU2305708C2 (ru) * 2001-10-02 2007-09-10 Энститю Клейтон Де Ля Решерш Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение
CA2468861C (en) 2001-12-05 2012-06-12 The Regents Of The University Of California Robotic microscopy systems
ES2290449T3 (es) 2002-04-09 2008-02-16 Sanofi Pasteur Limited Acido nucleico de cea modificado y vectores de expresion.
JP4343708B2 (ja) * 2002-04-26 2009-10-14 アンスティテュ ナシナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル−イ．エヌ．エス．ウ．エール．エム． 改良型キメラ糖タンパク質と、類型化されたレンチウイルス
AU2003291426A1 (en) * 2002-11-12 2004-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Human Services, The National Institutes Of Health Gp64-pseudotyped vectors and uses thereof
US20050014166A1 (en) * 2002-11-22 2005-01-20 Institut Clayton De La Recherche Compositions and systems for the regulation of genes
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US8026819B2 (en) * 2005-10-02 2011-09-27 Visible Assets, Inc. Radio tag and system
CA2536599A1 (en) * 2003-08-29 2005-03-10 Kaneka Corporation Method of constructing transgenic bird using lentivirus vector and transgenic bird obtained thereby
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
EP1773403B1 (de) * 2004-07-09 2018-04-25 The University of North Carolina At Chapel Hill Auf alphavirus basierende adjuvanzien
EP1856250B1 (de) * 2005-02-15 2013-07-24 The University of North Carolina At Chapel Hill Neue lebende virus-impfstoffe
WO2007089780A2 (en) * 2006-01-30 2007-08-09 Licentia, Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
JP2010505442A (ja) * 2006-10-10 2010-02-25 ビロメッド カンパニー， リミテッド 安全性の改善された発現ベクター
EP2089513A1 (de) 2006-12-07 2009-08-19 Publiekrechtelijke rechtspersoon Academisch Ziekenhuis Leiden h.o.d.n. Leids Universitair Medisch Centrum Verwendung eines varicellovirus-tap-hemmers zur induktion von tumor- oder virenspezifischer immunität gegen teipp
CN101705246B (zh) * 2007-04-29 2012-06-27 中国农业科学院哈尔滨兽医研究所 慢病毒基因转移载体、其制备方法和应用
JP2011500036A (ja) 2007-10-15 2011-01-06 ザ ユニバーシティー オブ クイーンズランド 構築物系およびその使用
WO2009065080A1 (en) 2007-11-16 2009-05-22 San Diego State University Research Foundation Compositions and method for manipulating pim-1 activity in circulatory system cells
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2393917B1 (de) 2009-02-03 2016-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Kulturboden für epithelstammzellen und organellen, die diese stammzellen umfassen
EP2412800A1 (de) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Leberorganoid, Verwendungen davon und Kultivierungsverfahren zum Erhalten davon
CN101532031B (zh) * 2009-03-03 2011-04-20 上海吉盛制药技术有限公司 非整合慢病毒载体系统及其制备与应用
WO2011034421A1 (en) 2009-09-16 2011-03-24 Stichting Het Nederlands Kanker Instituut Fra-1 target genes as drug targets for treating cancer
EP2305717A1 (de) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Hemmung von TNIK zur Behandlung von Darmkrebs
EP2319918B1 (de) * 2009-11-10 2013-01-16 Centre National De La Recherche Scientifique Vektor auf Lentivirus beruhend und dessen Verwendung bei der zielgerichteten Evolution von genomischen Regionen, Genen und Polynukleotiden
US20120027725A1 (en) * 2009-11-30 2012-02-02 Galvin Jeffrey A Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules to treat liver cancer
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
EP2605798A1 (de) 2010-07-12 2013-06-26 Universidad Autònoma de Barcelona Gentherapiezusammensetzung für die behandlung von diabetes
WO2012047093A1 (en) 2010-10-05 2012-04-12 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of the sjögren's syndrome
EP2465928A1 (de) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Behandlung von Th17-vermittelten Krankheiten
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
US9943574B2 (en) 2012-06-27 2018-04-17 Arthrogen B.V. Combination for treating an inflammatory disorder
RS54944B1 (sr) 2012-07-12 2016-11-30 Proqr Therapeutics Ii Bv Oligonukleotidi za pravljenje promena u sekvencama ciljanih rnk molekula prisutnih u živoj ćeliji
EP2692868A1 (de) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
US9730996B2 (en) 2012-10-24 2017-08-15 Texas Biomedical Research Institute Involucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
CA2906643A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Isolation of non-embryonic stem cells and uses thereof
US20160251680A1 (en) 2013-11-05 2016-09-01 Clontech Laboratories, Inc. Dry transfection compositions and methods for making and using the same
EP3137100B1 (de) 2014-04-15 2023-12-20 University Of Virginia Patent Foundation Isolierte t-zellenrezeptoren und verfahren zur verwendung davon
EP3031923A1 (de) * 2014-12-11 2016-06-15 Institut Pasteur Lentivirale, vektorbasierte immunogene Zusammensetzung gegen Japanische Enzephalitis
US11033638B2 (en) 2015-01-07 2021-06-15 Universität Autonoma De Barcelona Single-vector gene construct comprising insulin and glucokinase genes
CA3288232A1 (en) 2015-10-23 2025-11-29 Jackson Lab Nicotinamide is used in the treatment and prevention of neurodegenerative eye disorders (for example, glaucoma).
FI3380620T3 (fi) 2015-11-23 2024-08-01 Novartis Ag Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja
WO2017096432A1 (en) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
EP4099015A1 (de) 2016-06-10 2022-12-07 Gadeta B.V. Neuartiges verfahren zur identifizierung von delta-t-zell (oder gamma-t-zell)-rezeptorketten oder teilen davon, die eine antitumor- oder antiinfektionsreaktion vermitteln
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
CA3050917A1 (en) 2017-01-30 2018-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant virus vectors for the treatment of glycogen storage disease
EP3624823A1 (de) 2017-05-18 2020-03-25 UMC Utrecht Holding B.V. Zusammensetzungen und verfahren für zellgerichtete therapien
EP3630160A1 (de) 2017-05-24 2020-04-08 Universitat Autònoma De Barcelona Konstrukt zur viralen expression mit einer codierungssequenz des fibroblasten-wachstumsfaktors 21 (fgf21)
IL270882B2 (en) 2017-05-24 2024-02-01 Univ Barcelona Autonoma Viral expression vectors containing the coding sequence for FIBROBLAST GROWTH FACTOR 21 (FGF21
US11597917B2 (en) 2017-07-06 2023-03-07 The Medical College Of Wisconsin, Inc. In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders
GB201721615D0 (en) 2017-12-21 2018-02-07 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures
WO2019133810A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
CA3096458A1 (en) 2018-04-12 2019-10-17 Umoja Biopharma, Inc. Viral vectors and packaging cell lines
EP3784695B1 (de) 2018-04-27 2023-08-09 The Medical College of Wisconsin, Inc. Verwendung von lentivektor-transduzierten t-rapa-zellen zur linderung von lysosomalen speicherkrankheiten
WO2019219979A1 (en) 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
WO2020018715A1 (en) 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
CA3120923A1 (en) 2018-11-26 2020-06-04 Universitat Autonoma De Barcelona Fibroblast growth factor 21 (fgf21) gene therapy
SG11202104337PA (en) 2018-11-26 2021-05-28 Massachusetts Inst Technology Compositions and methods for immune tolerance
WO2020239995A1 (en) 2019-05-31 2020-12-03 Universitat Autònoma De Barcelona Insulin gene therapy
ES2948620T3 (es) 2019-07-10 2023-09-14 Masonic Medical Res Laboratory Vgll4 con elemento regulador CIS de UCP-1 y método de uso del mismo
WO2021055801A1 (en) 2019-09-18 2021-03-25 The Medical College Of Wisconsin, Inc. Improved alpha-galactosidase protein for enzyme replacement therapy (ert) and methods of use
AU2021264465A1 (en) 2020-04-27 2022-12-15 University Of Iowa Research Foundation Compositions and methods for the treatment of cystic fibrosis
KR20230017845A (ko) 2020-05-26 2023-02-06 유니버시타트 아우토노마 데 바르셀로나 중추 신경계 장애에 대한 섬유아세포 성장 인자 21(fgf21) 유전자 요법
CA3184784A1 (en) 2020-05-27 2021-12-02 The Medical College Of Wisconsin, Inc. Improved lentiviral vector transfer plasmid and methods of use
US12577540B2 (en) 2020-12-10 2026-03-17 Sarepta Therapeutics, Inc. Suspension mode seed train development for adherent cells
US20250345463A1 (en) 2021-01-30 2025-11-13 Universitat Autònoma De Barcelona Gene therapy for monogenic diabetes
WO2022221462A1 (en) 2021-04-13 2022-10-20 Kriya Therapeutics, Inc. Vector constructs for delivery of nucleic acids encoding therapeutic vlcad or mcad and methods of using the same
EP4089171A1 (de) 2021-05-12 2022-11-16 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Rekombinante tert-codierende virale genome und vektoren
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
IL310185A (en) 2021-07-16 2024-03-01 Academisch Ziekenhuis Leiden Oligonucleotide for inhibiting quaking activity
AU2023259404A1 (en) 2022-04-29 2024-11-28 Kriya Therapeutics, Inc. Insulin and glucokinase gene therapy compositions and its use for treating diabetes
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
US20240075068A1 (en) 2022-07-15 2024-03-07 Gadeta B.V. Novel soluble gamma T-cell (or soluble delta T-cell) receptor chains (or soluble gammadelta T-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
EP4584383A1 (de) 2022-09-07 2025-07-16 Universitat Autònoma De Barcelona Beta-hexosaminidase-vektoren
WO2024100136A1 (en) 2022-11-08 2024-05-16 Gadeta B.V. Novel method for obtaining gamma t-cell (or delta t-cell) receptor chains (or gamma delta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
WO2024149284A1 (en) * 2023-01-10 2024-07-18 Nanjing Legend Biotech Co., Ltd. Regulatory sequences and uses thereof
WO2024259299A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Compositions and methods for identification of vhh antibodies that bind a target antigen

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
JPH04503306A (ja) 1989-02-01 1992-06-18 ザ・ジェネラル・ホスピタル・コーポレーション 単純ヘルペスウイルス１型発現ベクター
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US5849571A (en) 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5376542A (en) 1992-04-27 1994-12-27 Georgetown University Method for producing immortalized cell lines using human papilluma virus genes
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
WO1995014091A2 (en) 1993-11-18 1995-05-26 Chiron Viagene, Inc. Compositions and methods for utilizing conditionally lethal genes
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5750396A (en) 1995-05-08 1998-05-12 St. Judes Children's Research Hospital Stable virus packaging cell lines
US6150511A (en) 1995-05-09 2000-11-21 Fox Chase Cancer Center Chimeric enzyme for promoting targeted integration of foreign DNA into a host genome
WO1996035798A1 (en) 1995-05-10 1996-11-14 Introgene B.V. Improved retroviral vectors, especially suitable for gene therapy
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
PT904392E (pt) * 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors

Also Published As

Publication number Publication date
US20010044149A1 (en) 2001-11-22
DE69829471T2 (de) 2006-04-13
JP2002510199A (ja) 2002-04-02
IL132463A0 (en) 2001-03-19
US6521457B2 (en) 2003-02-18
JP4390860B2 (ja) 2009-12-24
KR20010012543A (ko) 2001-02-15
US20030148522A1 (en) 2003-08-07
AU7577798A (en) 1998-12-08
WO1998051810A1 (en) 1998-11-19
CN1247788C (zh) 2006-03-29
EP0981636A1 (de) 2000-03-01
ATE291632T1 (de) 2005-04-15
EP0981636B1 (de) 2005-03-23
NO995382D0 (no) 1999-11-03
KR100556864B1 (ko) 2006-03-10
CA2288328A1 (en) 1998-11-19
DE69829471D1 (de) 2005-04-28
AU741747B2 (en) 2001-12-06
NZ500740A (en) 2001-02-23
US6277633B1 (en) 2001-08-21
CN1261404A (zh) 2000-07-26

Similar Documents

Publication Publication Date Title
NO995382D0 (no) Lentivirus baserte genoverföringsvektorer
Zaiss et al. RNA 3′ readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy
EP0512017B1 (de) Vakzine
Cui et al. Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function
Browning et al. Primate and feline lentivirus vector RNA packaging and propagation by heterologous lentivirus virions
GB2331522B (en) Lentiviral vectors
CA2370103A1 (en) Method and means for producing high titer, safe, recombinant lentivirus vectors
US12091674B2 (en) Lentiviral vector and method for delivering exogenous RNA by the lentiviral vector
EP0702716A4 (de) Gentherapy bei hiv-infektion und aids mit hilfe von ribozymen
WO2001081608A3 (en) Viral vectors for use in monitoring hiv drug resistance
ATE211766T1 (de) Gentechnologische herstellung von impfstoffen gegen aids und andere retrovirale krankheiten
WO2003092594A3 (en) Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
JP2003508017A5 (de)
WO2001055362A3 (en) Hybrid adeno-retroviral vector for the transfection of cells
Pietschmann et al. An evolutionarily conserved positively charged amino acid in the putative membrane-spanning domain of the foamy virus envelope protein controls fusion activity
WO2003093417A3 (en) Lentiviral vector particles resistant to complement inactivation
Rosen et al. The 3′ region of bovine leukemia virus genome encodes a trans‐activator protein.
FR2606029B2 (fr) Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus
AU4952500A (en) Packaging cell
WO2000040741A3 (en) Lentivirus vector system
WO2001044458A3 (en) Bovine immunodeficiency virus (biv) based vectors
WO2002008436A3 (en) Mini-adenoviral vector system for vaccination
Oh et al. Construction and characterization of a replication-competent retroviral shuttle vector plasmid
Bansal et al. Characterization of the R572T point mutant of a putative cleavage site in human foamy virus Env
Joshi et al. Efficient replication, integration, and packaging of retroviral vectors with modified long terminal repeats containing the packaging signal

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application